The Effect of Mirogabalin on the Treatment of Intractable Postherpetic Neuralgia Not Responding Appropriately to Pregabalin: A Case Report

• Published in: International journal of pain Vol. 14; no. 1; pp. 18 - 22
• Main Authors: Jeong, Jeong, Hwang, In Eob, Woo, Sungwon, Moon, Jee Youn
• Format: Journal Article
• Language: English
• Published: 대한통증연구학회 30.06.2023
• Subjects: 마취과학
• ISSN: 2233-4793; 2233-4807
• DOI: 10.56718/ijp.22-018

Postherpetic neuralgia (PHN) is the most common but challenging complication of herpes zoster due to long-lasting intractable neuropathic pain. Routine pharmacologic treatments of PHN include anticonvulsants (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline), opioids (e.g., oxycodone, morphine). However, those medications have limitations due to side effects inclusive of peripheral edema, nausea, vomiting and somnolence, or insufficient analgesic effect. Mirogablin, a novel voltage-gated calcium channel (VGCC) selective α2δ ligand, has been recently approved as a drug to treat peripheral neuropathic pain. In this case report, we represent a 77-year-old patient with intractable PHN who achieved successful pain relief with intake of mirogabalin with less side effects. KCI Citation Count: 0